Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Acetyl-coenzyme-A carboxylase inhibition shows early promise for acne vulgaris

Key clinical point: A potent oral inhibitor of acetyl-coenzyme-A carboxylase dramatically reduced facial sebum production.

Major finding: Oral therapy for 2 weeks with the acetyl-coenzyme-A carboxylase inhibitor (200 mg twice daily) was well tolerated and reduced baseline sebum production by 49%. This effect was not observed in a small placebo comparator group.

Study details: A study of 22 healthy human volunteers, 9 individuals with acne vulgaris, and hamster and guinea pig models.

Disclosures: Pfizer provided funding. Dr. Esler and 12 coinvestigators are Pfizer employees and stockholders. Two additional coinvestigators are former Pfizer employees while three are current or prior scientific consultants for Pfizer.


Esler WP et al. Sci Transl Med. 2019 May 15. doi: 10.1126/scitranslmed.aau8465.